Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.3.0.814
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash Flows from Operating Activities:    
Net Loss $ (38,808) $ (16,673)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation and amortization 17 17
Noncash interest expense 167 555
Amortization of debt discount 143 0
Stock-based compensation expense 11,896 4,082
Change in fair value of investment 65 293
Asset impairment loss 0 723
Unrealized gain on marketable securities (11) 0
Increase (decrease) in cash resulting from changes in assets and liabilities:    
Prepaid expenses and other current assets (394) (31)
Accounts payable and accrued expenses 4,375 (1,366)
Interest payable (2) (84)
End of term fee associated with Hercules Note 0 (398)
Other long term liabilities (687) 75
Net cash used in Operating Activities (23,239) (12,807)
Cash Flows from Investing Activities:    
Purchase of marketable securities, at fair value (19,938) 0
Purchase of short- term investment 0 (345)
Purchase of long-term investment 0 (250)
Purchase of property and equipment (94) 0
Purchase of license (1,250) 0
Payment to related parties - CB Pharma Acquisition Corp (130) 0
Net cash used in Investing Activities (21,412) (595)
Cash Flows from Financing Activities:    
Payment of Hercules Note 0 (13,655)
Proceeds from issuance of common stock 0 606
Proceeds from the exercise of stock options 216 0
Proceeds from issuance of common stock under ESPP 26 0
Proceeds from subsidiary's public offering 12,575 0
Payment of costs related to subsidiary's public offering (1,507) 0
Payment of costs related to the issuance of common stock 0 (32)
Proceeds from IDB note 0 14,009
Payment of debt issue costs associated with IDB Note 0 (9)
Proceeds from NSC note 10,000 0
Payment of debt issue costs associated with NSC Note (855) 0
Transfer of restricted cash 0 (15,446)
Net cash provided by (used in) Financing Activities 20,455 (14,527)
Net decrease in cash and cash equivalents (24,196) (27,929)
Cash and cash equivalents at beginning of period 49,759 99,521
Cash and cash equivalents at end of period 25,563 71,592
Supplemental disclosure of cash flow information:    
Cash paid for interest 80 614
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of restricted stock $ 1 $ 4